Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29986651 | 0.96 | MAPT (0.75) | MAPTALDH1A1LMNASMN1; SMN2GPR119 | |
| SCHEMBL30985158 | 0.91 | MAPT (0.65) | MAPTALDH1A1LMNASMN1; SMN2GPR119 | |
| SCHEMBL25176363 | 0.90 | MAPT (0.73) | MAPTALDH1A1LMNASMN1; SMN2GPR119 | |
| SCHEMBL25845748 | 0.90 | MAPT (0.76) | MAPTALDH1A1LMNASMN1; SMN2GPR119 | |
| SCHEMBL30985212 | 0.88 | MAPT (0.67) | MAPTALDH1A1LMNASMN1; SMN2GPR119 | |
| SCHEMBL30985071 | 0.88 | MAPT (0.61) | MAPTALDH1A1LMNASMN1; SMN2GPR119 | |
| SCHEMBL30985104 | 0.88 | MAPT (0.64) | MAPTALDH1A1LMNASMN1; SMN2GPR119 | |
| SCHEMBL30981102 | 0.88 | MAPT (0.63) | MAPTALDH1A1LMNASMN1; SMN2GPR119 | |
| SCHEMBL30981331 | 0.88 | ALDH1A1 (0.57) | MAPTALDH1A1LMNAGPR119CNR1 | |
| SCHEMBL30981045 | 0.87 | MAPT (0.60) | MAPTALDH1A1LMNASMN1; SMN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4652161-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | Uppthera, Inc. (KR) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025108404-A1 | HETEROCYCLIC COMPOUND OF BIFUNCTIONAL CHIMERA FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND USE THEREOF | 广东东阳光药业股份有限公司 | 2025-05-30 | — | — | WO | disclosed |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| EP-4428130-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024155112-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | UPPTHERA, INC. (KR) | 2024-07-25 | — | — | WO | disclosed |
| CN-118159532-A | Compound with BTK protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024059808-A1 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | RECURIUM IP HOLDINGS, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| CN-111892577-B | Compounds and methods for androgen receptor targeted degradation | 阿尔维纳斯运营股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| WO-2023080732-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-05-11 | — | — | WO | disclosed |
| CN-111892577-A | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2020-11-06 | — | — | CN | disclosed |
| US-10584101-B2 | Compounds and methods for the targeted degradation of androgen receptor | Arvinas, Inc. (US) | 2020-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | MAPT 2938/4885ALDH1A1 798/4885LMNA 2916/4885 |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | MAPT 3790/4885ALDH1A1 4704/4885LMNA 4396/4885 |
| US-10584101-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | MAPT 2970/4885ALDH1A1 824/4885LMNA 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.